Business Case

Simulated pricing discount expectations and business impact of four successive label expansions of a blockbuster oncology franchise 

Our client, a large pharmaceutical company, was poised to expand their blockbuster oncology assets into four new tumor types within a 24-month period and required insight into optimal pricing and discounting strategies. LSC developed a comprehensive approach, simulating the break-even point price and associated discount required for each upcoming indication, resulting in the formulation of four distinct price discount scenarios. An interactive model was developed, allowing our client to tailor variations in launch timelines and contrast the annual therapy cost of their asset with those of competitors. The rigorous analysis provided our client with clear, data-driven recommendations, informing internal and external negotiations for the two years to follow.